At 8:15 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hig ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Murano Global Investments Plc (MRNO) is up 146% at $3.35 [3] - Kustom Entertainment, Inc. (KUST) is up 34% at $2.84 [3] - Ainos, Inc. (AIMD) is up 34% at $2.32 [3] - Stride, Inc. (LRN) is up 29% at $94.10 [3] - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is up 18% at $2.40 [3] - Battalion Oil Corporation (BATL) is up 16% at $3.83 [3] - C3.ai, Inc. (AI) is up 15% at $14.58 [3] - Lantronix, Inc. (LTRX) is up 14% at $7.87 [3] - Nextpower Inc. (NXT) is up 13% at $120.00 [3] - High Roller Technologies, Inc. (ROLR) is up 7% at $7.56 [3] Premarket Losers - Flora Growth Corp. (FLGC) is down 34% at $7.20 [4] - TEN Holdings, Inc. (XHLD) is down 29% at $2.47 [4] - Global Interactive Technologies, Inc. (GITS) is down 22% at $3.25 [4] - 5E Advanced Materials, Inc. (FEAM) is down 15% at $2.70 [4] - Vyome Holdings, Inc. (HIND) is down 14% at $2.79 [4] - Altimmune, Inc. (ALT) is down 11% at $5.48 [4] - BiomX Inc. (PHGE) is down 10% at $6.22 [4] - Qorvo, Inc. (QRVO) is down 9% at $74.94 [4] - Nuwellis, Inc. (NUWE) is down 9% at $3.45 [4] - Brenmiller Energy Ltd (BNRG) is down 9% at $2.90 [4]

NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account f ...

Group 1 - BiomX (PHGE) has entered into definitive agreements for a private investment in public equity financing, expecting gross proceeds of approximately $3 million before deducting fees and expenses [1] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this private placement [1] - The company will issue Series Y Convertible Preferred Stock with a stated value of $1,000 per share, along with warrants valued up to $3.3 million, for a total purchase price of $3 million [1] Group 2 - The Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and will mature one year from the closing date [1] - Each share of Series Y Convertible Preferred Stock is convertible into common stock, subject to stockholder approval as required under NYSE American rules [1] - The company will issue warrants to acquire up to 3,300,000 shares of common stock, with a five-year term and an initial exercise price of $2.00 [1] Group 3 - The private placement is expected to close on or about December 30, pending the satisfaction of customary closing conditions [1]

Core Viewpoint - BiomX Inc. (PHGE) has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for BiomX reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for BiomX has increased by 11.7%, indicating positive revisions in earnings estimates [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, highlighting superior earnings estimate revisions [9][10]. - Stocks rated Zacks Rank 1 have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [7].

Core Viewpoint - BiomX Inc. has announced a private placement financing expected to raise approximately $3.0 million to support its bacteriophage programs and evaluate strategic alternatives [1][7]. Group 1: Private Placement Details - The private placement involves the issuance of Series Y Convertible Preferred Stock with a stated value of $1,000 per share, along with warrants, for a total purchase price of $3.0 million [3]. - Each share of Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and has a maturity of one year from the closing date [4]. - The company will issue warrants to acquire up to 3,300,000 shares of common stock, with an initial exercise price of $2.00 and a five-year term [5]. Group 2: Use of Proceeds - The net proceeds from the private placement will be used to assess opportunities in the company's bacteriophage programs, particularly BX011 for Staphylococcus aureus infections related to diabetic foot infections, and for general corporate purposes [7]. Group 3: Regulatory and Closing Information - The securities sold in the private placement have not been registered under the Securities Act and were offered in reliance on exemptions from registration requirements [6]. - The private placement is expected to close on or about December 30, 2025, subject to customary closing conditions [5]. Group 4: Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies to target harmful bacteria for chronic diseases with significant unmet needs [9]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [9].

Core Viewpoint - BiomX Inc. has announced a private placement financing expected to raise approximately $3.0 million to support its bacteriophage programs and general corporate purposes [1][7]. Private Placement Details - The private placement involves the issuance of Series Y Convertible Preferred Stock with a stated value of $1,000 per share, along with warrants, for a total purchase price of $3.0 million [3]. - Each share of Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and has a maturity of one year from the closing date [4]. - The company will issue warrants to acquire up to 3,300,000 shares of common stock, with an initial exercise price of $2.00 and a five-year term [5]. Use of Proceeds - The net proceeds from the private placement will be used to assess opportunities in bacteriophage programs, including BX011 for Staphylococcus aureus infections, and for general corporate purposes [7]. Regulatory and Compliance Information - The securities sold in the private placement have not been registered under the Securities Act of 1933 and were offered in reliance on exemptions from registration requirements [6]. - The company plans to file a registration statement with the SEC to register the resale of shares issuable upon conversion of the Series Y Convertible Preferred Stock and exercise of the warrants [6]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies to target harmful bacteria for chronic diseases with significant unmet needs [9]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [9].

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index dropping over 200 points, down 0.46% to 47,733.58. The NASDAQ fell 0.32% to 23,501.92, and the S&P 500 also decreased by 0.46% to 6,838.69 [1] - In the commodities market, oil prices fell by 1.6% to $59.14, gold decreased by 0.6% to $4,219.60, silver dropped 1.1% to $58.395, and copper fell 0.7% to $5.4225 [5] Sector Performance - Information technology shares increased by 0.6% on Monday, while communication services stocks saw a decline of 2.1% [1] European Market - European shares showed mixed results, with the eurozone's STOXX 600 falling 0.07%, Spain's IBEX 35 Index rising 0.14%, London's FTSE 100 down 0.23%, Germany's DAX 40 gaining 0.07%, and France's CAC 40 falling 0.08% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei rising 0.18%, Hong Kong's Hang Seng dipping 1.23%, China's Shanghai Composite increasing by 0.54%, and India's BSE Sensex declining by 0.71% [7] Company News - Structure Therapeutics Inc. saw its shares surge 100% to $68.95 following the announcement of positive topline data from its ACCESS clinical program for aleniglipron, aimed at treating obesity [9] - Wave Life Sciences Ltd. shares increased by 124% to $16.77 after reporting positive interim Phase 1 data for its obesity drug WVE-007 [9] - Fulcrum Therapeutics, Inc. shares rose 63% to $14.50 after initial results from its Phase 1b PIONEER trial of Pociredir in sickle cell disease showed promising outcomes [9] - SMX (Security Matters) Public Limited Company shares dropped 57% to $141.56 after a significant rise of 135% on the previous Friday [9] - BiomX Inc. shares fell 33% to $3.4398 after discontinuing its Phase 2b trial of BX004 in cystic fibrosis patients [9] - Meihua International Medical Technologies Co., Ltd. shares decreased by 38% to $8.66 following the announcement of its delisting from Nasdaq [9]

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 200 points, down 0.46% to 47,733.58. The NASDAQ decreased by 0.32% to 23,501.92, and the S&P 500 also fell 0.46% to 6,838.69 [1] Sector Performance - Information technology shares increased by 0.6% on the same day, while communication services stocks dropped by 2.1% [1] Commodity Prices - Oil prices fell by 1.6% to $59.14, gold decreased by 0.6% to $4,219.60, silver dropped by 1.1% to $58.395, and copper fell by 0.7% to $5.4225 [5] European Market Performance - European shares showed mixed results, with the eurozone's STOXX 600 down 0.07%, Spain's IBEX 35 Index up 0.14%, London's FTSE 100 down 0.23%, Germany's DAX 40 up 0.07%, and France's CAC 40 down 0.08% [6] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei rising 0.18%, Hong Kong's Hang Seng down 1.23%, China's Shanghai Composite up 0.54%, and India's BSE Sensex declining 0.71% [7] Company News - Structure Therapeutics Inc. saw its shares surge 100% to $68.95 following positive topline data from its clinical program for obesity treatment [9] - Wave Life Sciences Ltd. shares increased by 124% to $16.77 after reporting positive interim Phase 1 data for its obesity drug [9] - Fulcrum Therapeutics, Inc. shares rose 63% to $14.50 after initial results from its Phase 1b trial showed promising outcomes in sickle cell disease [9] - SMX Public Limited Company shares dropped 57% to $141.56 after a significant rise the previous day [9] - BiomX Inc. shares fell 33% to $3.4398 after discontinuing its Phase 2b trial for cystic fibrosis [9] - Meihua International Medical Technologies Co., Ltd. shares decreased by 38% to $8.66 following the announcement of its delisting from Nasdaq [9]

Core Insights - BiomX has decided to discontinue the Phase 2b trial of BX004 for cystic fibrosis due to high rates of adverse events identified in a safety review by the Data Monitoring Committee [1][2] - The company is focusing on its phage program BX011 for Staphylococcus aureus infections related to diabetic foot infections while implementing cost-cutting measures, including workforce reduction [1][2][3] Company Overview - BiomX is a clinical-stage company developing natural and engineered phage therapies aimed at treating chronic diseases with significant unmet medical needs [4] - The company utilizes its BOLT platform to customize phage compositions targeting specific bacterial pathogens [4]